GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view
(Reuters) – Consumer healthcare group Haleon expects 2023 organic revenue growth towards the upper end of its 4%-6% forecast, it said on Thursday, on strong demand and the restocking of its respiratory health products due to a bad cold and flu season.
The company, the world’s biggest standalone consumer health business that sells non-prescription drugs, vitamins and oral care products, kept the rest of its full-year 2023 outlook unchanged.
Haleon was carved out of British drugmaker GSK in July last year.
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Janane Venkatraman)